).
Introduction
Venovenous extracorporeal membrane oxygenation (VV ECMO) is being used for treatment of refractory acute res piratory distress syndrome (ARDS). It has been shown to improve outcomes in patients with respiratory failure. [1] [2] [3] Unfractionated heparin (UFH) is the most widely used agent to maintain anticoagulation in ECMO. The therapeutic effect of UFH is monitored by activated coagulation time (ACT) and activated partial thromboplastin time (aPTT). However, re cent experiences have suggested that even when both these parameters are in desired ranges, patients still carry a risk of bleeding or circuit thrombosis. 4 Thromboelastography (TEG) is a viscoelastic hemostatic test that provides overall infor mation on clot initiation, clot kinetics, and resolution of the clot. The authors hereby report the case of 16yearold girl in whom TEG revealed a hypercoagulable state when ACT and aPTT were in desired range.
Case Report
A 16yearold girl was admitted with history of maculopap ular eruptions all over her body and pneumonia. She de veloped ARDS within 24 hours of admission with a Murray score of 4.0 and was unable to maintain a saturation of > 85%.
A VV ECMO, with a right femoral vein inflow cannula (21F) and a right internal jugular outflow cannula (17F), was ini tiated. After initiation of ECMO, her PaO 2 stabilized between 50 and 60 mm Hg. The ECMO flow was 2.5 L/min with a FiO 2 on ECMO of 100%. UFH was given in a bolus of 100 U/kg at the time of cannulation, and an infusion of heparin was started at 10 U/kg/h to maintain ACT of 170 to 200 seconds. The fol lowing cutoffs were followed: platelet 100,000/μL, interna tional normalized ratio (INR) < 1.5, aPTT 45 to 70 seconds, ACT 170 to 200 seconds, and fibrinogen > 200 mg/dL.
Broadspectrum antibiotics for grampositive and gram negative bacteria were started following which the pa tient started improving on day 3 of ECMO. Initially, she was given enteric feeding, and in view of prolonged ventilation, a percutaneous tracheostomy was performed. The heparin infusion was stopped for 2 hours before performing the tra cheostomy. As soon as the tracheostomy was completed, a bolus of 100 U/kg heparin was administered and the infusion was started on 10 U/kg/h. After 12 hours of tracheostomy, bleeding occurred from tracheostomy site (►Fig. 1). A TEG was performed to evaluate the coagulation function. The first TEG revealed an inadequate heparin effect, low platelet func tion, and a hypercoagulable state (►Fig. 2A). The heparin was increased to 15 U/kg/h to delay the initiation of clot forma tion (prolong the R and K time). A repeat TEG after 24 hours Thromboelastography in Venovenous ECMO for ARDS Singh et al.
was weaned off ventilation 10 days later. Her ECMO duration was 8 days and hospital stay was 28 days. She was doing well on her first followup.
Discussion
The trace of TEG displays a R time that relates to the initiation of clot formation (common, intrinsic, and extrinsic pathway), K time (time taken for the clot to reach up to 20 mm from 2 mm, clot kinetics), maximum amplitude (80% platelets and 20% fibrinogen), and α angle (rate of clot formation).
5 Clot strength (G) is the shear elastic modulus strength of clot and is expressed in dynes/cm 2 . The normal values for (TEMA Framar Biomedica, Hemologix) R time, K time, α angle, max imum amplitude, and G are 5 to 11 minutes, 1.5 to 4.5 min utes, 44 to 66 degrees, 53 to 70 mm, and 5,500-12,000 dynes/ cm 2 , respectively. At the initiation of ECMO, there is dilution of coagulation factors, and a consumption coagulopathy also ensues causing decrease in coagulation factors and fibrinogen levels. 6, 7 There is an immediate decrease in platelet count as well. 8, 9 Con ventionally, the parameters measured during ECMO include platelets, PT, aPTT, fibrinogen, and ACT. Antifactor Xa (fXa) still revealed a normal trace and the heparin was further increased to 20 U/kg/h. The third TEG (►Fig. 2C) demonstrat ed the therapeutic effect of heparin and normal platelet func tion. The patient was weaned off ECMO 2 days later and the TEG trace shown in ►Fig. 2D was recorded after decannula tion and reversal with protamine. She improved steadily and levels and heparin levels (0.2-0.4 U/mL) may also be mea sured for direct evidence. The anticoagulation targets are less on VV ECMO as compared to venoarterial (VA) ECMO as the risk of ischemia of the limb is less. The cutoffs followed for VV ECMO include platelet 100,000/µL, INR < 1.5, aPTT 45 to 70 seconds, ACT 170 to 200 seconds, and fibrinogen > 200 mg/dL in contrast to cutoffs for VA ECMO-platelet 100,000/µL, INR < 2.0, aPTT 70 to 100 seconds, ACT 200 to 240 seconds, and fibrinogen > 150 mg/dL. 10 In case of VV ECMO, the anticoagu lation may be withheld for longer periods as well because the risk of stroke is not related to the circuit.
It has been demonstrated that aPTT correlates with an tifXa levels, but there is no correlation between ACT and an tifXa levels. 11, 12 Zmuda et al studied the relation between aPTT and antifXa levels. They found that, during heparin infusion, when the antifXa levels progressively increase to 0.1, 0.2, 0.3, 0.4, and 0.5 U/mL, the baseline aPTT of 28 seconds increases to 30.4, 39.8, 51.1, 66.8, and 80.1 seconds, respectively. They also recorded that with antifXa levels of 0.1 U/mL, the R and K times on TEG increase to approximately 3 and 10 times, re spectively. In this patient, the authors kept on increasing the heparin infusion until the R and K times became 3 and 10 times of the normal, respectively (►Table 1). At 20 U/kg/h of heparin infusion, the TEG began to show a trace of optimal an ticoagulation. Also, the aPTT was 46.8 seconds establishing an appropriate therapeutic value (1.5 times the control).
The TEG was done in view of bleeding from the trache ostomy site. Instead, it revealed a hypercoagulable state (►Fig. 2A). It was explainable as PT and fibrinogen were within normal limits and aPTT was subtherapeutic. As the authors increased the heparin infusion to 20U/kg/h, the aPTT increased to therapeutic levels and TEG began to show a trace of optimal anticoagulation. However, if the PT time is prolonged and there is a hypercoagulable trace on TEG, a presumptive diagnosis of liver disease should be considered. The decrease in levels of Factor VII in liver disease may increase the PT.
In this patient, whose ACT is 168 seconds and aPTT is 45 seconds (control 35 seconds), TEG revealed a hyperco agulable state. There was a risk of circuit thrombosis and venous thromboembolism at such subtherapeutic anticoag ulation. With increase in heparin dosing and repeated TEG, optimal anticoagulation was achieved and maintained till decannulation.
In conclusion, TEG supplemented the conventional tests of hemostasis to achieve an optimal anticoagulation state during the ECMO. 
